|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Impact of gout on in-hospital outcomes of acute coronary syndrome-related hospitalizations and revascularizations: Insights from the national inpatient sample显示文摘BACKGROUND Previous studies have established a role of gout in predicting risk and prognosis of cardiovascular diseases. However, large-scale data on the impact of gout on inpatient outcomes of acute coronary syndrome (ACS)-related hospitalizations and post-revascularization is inadequate. AIM To evaluate the impact of gout on in-hospital outcomes of ACS hospitalizations, subsequent healthcare burden and predictors of post-revascularization inpatient mortality. METHODS We used the national inpatient sample (2010-2014) to identify the ACS and goutrelated hospitalizations, relevant comorbidities, revascularization and postrevascularization outcomes using the ICD-9 CM codes. A multivariable analysis was performed to evaluate the predictors of post-revascularization in-hospital mortality. RESULTS We identified 3144744 ACS-related hospitalizations, of which 105198 (3.35%) also had gout. The ACS-gout cohort were more often older white males with a higher prevalence of comorbidities. Coronary artery bypass grafting was required more often in the ACS-gout cohort. Post-revascularization complications including cardiac (3.2% vs 2.9%), respiratory (3.5% vs 2.9%), and hemorrhage (3.1% vs 2.7%) were higher whereas all-cause mortality was lower (2.2% vs 3.0%) in the ACSgout cohort (P < 0.001). An older age (OR 15.63, CI: 5.51-44.39), non-elective admissions (OR 2.00, CI: 1.44-2.79), lower household income (OR 1.44, CI: 1.17- 1.78), and comorbid conditions predicted higher mortality in ACS-gout cohort undergoing revascularization (P < 0.001). Odds of post-revascularization inhospital mortality were lower in Hispanics (OR 0.45, CI: 0.31-0.67) and Asians (OR 0.65, CI: 0.45-0.94) as compared to white (P < 0.001). However, postoperative complications significantly raised mortality odds. Mean length of stay, transfer to other facilities, and hospital charges were higher in the ACS-gout cohort. CONCLUSION Although gout was not independently associated with an increased risk of postrevascularization in-hospital mortality in ACS, it did increase postrevascularization complications. | Rupak Desai Tarang Parekh Hemant Goyal Hee Kong Fong Dipen Zalavadia Nanush Damarlapally Rajkumar Doshi Sejal Savani Gautam Kumar Rajesh Sachdeva | 2019 | World Journal of Cardiology2019，11，5： | 4 |
| 2 | Comparison of in-hospital outcomes between octogenarians and nonagenarians undergoing transcatheter aortic valve replacement: a propensity matched analysis显示文摘BackgroundAortic 阀门狭窄(作为) 在在 80 年上面的老病人是很普通的。在如此的病人的 Transcatheter 大动脉的阀门代替(TAVR ) 逐渐地正在被执行。寻求在与严重 AS.MethodThe 学习人口经历 TAVR 的九十至九十九岁的人估计死亡的 octogenarians 和九十至九十九岁的人和预言者之间的在里面医院结果差别的这研究从国家住院病人样品(网络信息服务) 被导出 2012-2014 使用 ICD-9 厘米过程为 TAVR 编码 35.05 和 35.06 的年。低于 80 岁的住院被排除。在执行倾向 20 以后匹配(1:2 ) ,在里面医院结果在匹配的队被比较。然后, multivariate 模型被开发在 nonagenarians.ResultsThere 分析在里面医院死亡的预言者是 11,630 个住院在八十至八十九岁并且在九十至九十九岁的人组的 5815 个住院。在里面医院死亡的主要结果(6% 对 4.1% , P 0.001 ) 在与 octogenarians 相比的九十至九十九岁的人是更高的。第二等的结果包括击(3.4%对2.8%, P 0.001 ),肾的失败(18.9%对17.3%, P 0.001 ),输血(35%对32.6%, P 0.001 ),脉管的复杂并发症(4.5%对3.5%, P 0.001 ),并且心律调整器培植(27.8%对24.8%, P 0.001 )在九十至九十九岁的人是更高的。在他们停留的长度没有差别。中部的费用(70,374 $ 对 65,381 $ , P 0.001 ) 与 nonagenarian.ConclusionsAlthough 在里面医院是稍微更高的死亡在九十至九十九岁的人是稍微更高的,它是可接受的。在死亡的这差别被更高的复杂并发症部分至少在九十至九十九岁的人解释。努力应该被成为能进一步在在这些组之间的在里面医院死亡缩小差别的复杂并发症到减少。 | Rajkumar Doshi Vaibhav Patel Priyank Shah | 2018 | Journal of Geriatric Cardiology2018，15，2： | 2 |
| 3 | COVID-19 and liver diseases,what we know so far显示文摘Coronavirus disease 2019(COVID-19)pneumonia outbreak started in December 2019.On March 12,2020,the World Health Organization(WHO)declared that the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)constitutes a pandemic,and as of May 2021,SARS-CoV-2 has infected over 167.3 million patients,including 3.4 million deaths,reported to WHO.In this review,we will focus on the relationship between SARS-CoV-2 infection and the liver.We will discuss how chronic liver diseases affect the COVID-19 disease course and outcomes.We will also discuss the SARS-CoV-2 effects on the liver,mechanisms of acute liver injury,and potential management plans. | Mohamed Elnaggar Ahmed Abomhya Ismail Elkhattib Nabila Dawoud Rajkumar Doshi | 2022 | World Journal of Clinical Cases2022，10，13： | 1 |
| 4 | Cardiac adverse events of immune checkpoint inhibitors in oncology patients:A systematic review and meta-analysis显示文摘BACKGROUND Immune checkpoint inhibitors(ICIs)are novel therapeutic agents used for various types of cancer.ICIs have revolutionized cancer treatment and improved clinical outcomes among cancer patients.However,immune-related adverse effects of ICI therapy are common.Cardiovascular immune-related adverse events(irAEs)are rare but potentially life-threatening complications.AIM To estimate the incidence of cardiovascular irAEs among patients undergoing ICI therapy for various malignancies.METHODS We conducted this systematic review and meta-analysis by searching PubMed,Cochrane CENTRAL,Web of Science,and SCOPUS databases for relevant interventional trials reporting cardiovascular irAEs.We performed a single-arm meta-analysis using OpenMeta[Analyst]software of the following outcomes:Myocarditis,pericardial effusion,heart failure,cardiomyopathy,atrial fibrillation,myocardial infarction,and cardiac arrest.We assessed the heterogeneity using the I2 test and managed to solve it with Cochrane’s leave-one-out method.The risk of bias was performed with the Cochrane’s risk of bias tool.RESULTS A total of 26 studies were included.The incidence of irAEs follows:Myocarditis:0.5%[95%confidence interval(CI):0.1%-0.9%];Pericardial effusion:0.5%(95%CI:0.1%-1.0%);Heart failure:0.3%(95%CI:0.0%-0.5%);Cardiomyopathy:0.3%(95%CI:-0.1%-0.6%);atrial fibrillation:4.6%(95%CI:1.0%-14.1%);Myocardial infarction:0.4%(95%CI:0.0%-0.7%);and Cardiac arrest:0.4%(95%CI:0.1%-0.8%).CONCLUSION The most common cardiovascular irAEs were atrial fibrillation,myocarditis,and pericardial effusion.Although rare,data from post market surveillance will provide estimates of the long-term prevalence and prognosis in patients with ICIassociated cardiovascular complications. | Nso Nso Daniel Antwi-Amoabeng Bryce D Beutler Mark B Ulanja Jasmine Ghuman Ahmed Hanfy Joyce Nimo-Boampong Sirri Atanga Rajkumar Doshi Sostanie Enoru Nageshwara Gullapalli | 2020 | World Journal of Cardiology2020，12，11： | 0 |
| 5 | Burden of atrial fibrillation in patients with rheumatic diseases显示文摘BACKGROUND Studies have suggested that atrial fibrillation(AF)in patients with rheumatic diseases(RD)may be due to inflammation.determine morbidity and mortality associated with AF in hospitalized patients with RD.METHODS The National inpatient sample database from October 2015 to December 2017 was analyzed to identify hospitalized patients with RD with and without AF.A subgroup analysis was performed comparing outcomes of AF among different RD.RESULTS The prevalence of AF was 23.9%among all patients with RD(n=3949203).Among the RD subgroup,the prevalence of AF was highest in polymyalgia rheumatica(33.2%),gout(30.2%),and pseudogout(27.1%).After adjusting for comorbidities,the odds of having AF were increased with gout(1.25),vasculitis(1.19),polymyalgia rheumatica(1.15),dermatopolymyositis(1.14),psoriatic arthropathy(1.12),lupus(1.09),rheumatoid arthritis(1.05)and pseudogout(1.04).In contrast,enteropathic arthropathy(0.44),scleroderma(0.96),ankylosing spondylitis(0.96),and Sjorgen’s syndrome(0.94)had a decreased association of AF.The mortality,length of stay,and hospitalization costs were higher in patients with RD having AF vs without AF.Among the RD subgroup,the highest mortality was found with scleroderma(4.8%),followed by vasculitis(4%)and dermatopolymyositis(3.5%).CONCLUSION A highest association of AF was found with gout followed by vasculitis,and polymyalgia rheumatica when compared to other RD.Mortality was two-fold higher in patients with RD with AF. | Muhammad Zubair Khan Kirtenkumar Patel Krunalkumar A Patel Rajkumar Doshi Vraj Shah Devina Adalja Zainulabedin Waqar Sona Franklin Neelesh Gupta Muhammad Hamdan Gul Shruti Jesani Steven Kutalek Vincent Figueredo | 2021 | World Journal of Clinical Cases2021，9，14： | 0 |
| 6 | Intracoronary brachytherapy for the treatment of recurrent drugeluting stent in-stent restenosis:A systematic review and metaanalysis显示文摘BACKGROUND We performed a meta-analysis on observational studies since randomized control trials are not available.We studied intracoronary brachytherapy(ICBT)and recurrent drug eluting stent in-stent restenosis(DES-ISR)to evaluate the procedural success,target lesion revascularization(TLR),incidence of myocardial infarction(MI)and all-cause mortality at 2 years follow-up.AIM To perform meta-analysis for patients undergoing ICBT for recurrent DES-ISR.METHODS We performed a systematic search of the PubMed/MEDLINE,Cochrane and DARE databases to identify relevant articles.Studies were excluded if intracoronary brachytherapy was used as a treatment modality for initial ISR and studies with bare metal stents.We used a random-effect model with DerSimonian&Laird method to calculate summary estimates.Heterogeneity was assessed using I2 statistics.RESULTS A total of 6 observational studies were included in the final analysis.Procedural angiographic success following intra-coronary brachytherapy was 99.8%.Incidence of MI at 1-year was 2%and 4.1%at 2-years,respectively.The incidence of TLR 14.1%at 1-year and 22.7%at 2-years,respectively.All-cause mortality at 1-and 2-year follow-up was 3%and 7.5%,respectively.CONCLUSION Given the observational nature of the studies included in the analysis,heterogeneity was significantly higher for outcomes.While there are no randomized controlled trials or definitive guidelines available for recurrent ISR associated with DES,this analysis suggests that brachytherapy might be the alternative approach for recurrent DES-ISR.Randomized controlled trials are required to confirm results from this study. | Irtqa Ilyas Ashish Kumar Devina Adalja Mariam Shariff Rupak Desai Yasar Sattar Saraschandra Vallabhajosyula Nageshwara Gullapalli Rajkumar Doshi | 2021 | World Journal of Cardiology2021，13，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员